title: Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7.
abstract: The novel cyclopenta[b]benzofuran, silvestrol, isolated from the fruits and twigs of Aglaia foveolata, has been found to exhibit very potent in vitro cytotoxic activity against several human cancer cell lines. Furthermore, it was active in the in vivo P388 murine leukemia model. In this study, the mechanism of cytotoxicity mediated by silvestrol in the LNCaP (hormone-dependent human prostate cancer) cell line was investigated. Silvestrol induced an apoptotic response, disrupted the mitochondrial trans-membrane potential and caused cytochrome c release into the cytoplasm. Immunoblot analysis indicated that, at the protein level, silvestrol produced an increase of Bcl-xl phosphorylation with a concomitant increase of bak. Furthermore, caspase-2, -9 and -10 appeared to be involved in silvestrol-mediated apoptosis. In contrast, the involvement of caspase-3 and -7 was not detected, either by immunoblot or caspase-3/-7-like activity analysis, indicating that these pathways do not play a crucial role in silvestrol-induced apoptosis. To investigate the relative contribution of the caspases, inhibition of apoptosis with four different cell-permeable inhibitors was studied (Boc-D-Fmk, Z-VDVAD-FMK Z-LEHD-FMK and Z-AEVD-FMK). Only the general caspase inhibitor, Boc-D-Fmk, completely inhibited the formation of apoptotic bodies. In contrast, caspase-2 and caspase-9 selective inhibitors induced about a 40% reduced apoptotic response, whereas the caspase-10 selective inhibitor caused about a 60% reduction in apoptosis compared to silvestrol only treated cells. Taken together, the studies described herein demonstrate the involvement of the apoptosome/mitochondrial pathway and suggest the possibility that silvestrol may also trigger the extrinsic pathway of programmed cell death signaling in tumor cells.
authors: Program for Collaborative Research in the Pharmaceutical Science and Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, IL 60612, USA.
authors: Soyoung
authors: S
authors: Kim
authors: Bang Yeon
authors: BY
authors: Hwang
authors: Bao-Ning
authors: BN
authors: Su
authors: Heebyung
authors: H
authors: Chai
authors: Qiuwen
authors: Q
authors: Mi
authors: A Douglas
authors: AD
authors: Kinghorn
authors: Robert
authors: R
authors: Wild
authors: Steven M
authors: SM
authors: Swanson
mesh_terms: D031602:Aglaia / Q000737:chemistry; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D053478:Apoptosomes / Q000187:drug effects / Q000502:physiology; D001593:Benzyl Compounds / Q000494:pharmacology; D053148:Caspase 3 / Q000378:metabolism*; D053179:Caspase 7 / Q000378:metabolism*; D045744:Cell Line, Tumor; D004347:Drug Interactions; D004789:Enzyme Activation; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology; D008297:Male; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects / Q000502:physiology; D008928:Mitochondria / Q000187:drug effects / Q000502:physiology; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D014315:Triterpenes / Q000494:pharmacology*; D001572:Benzofurans
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D053478:Apoptosomes; D001593:Benzyl Compounds; D053148:Caspase 3; D053179:Caspase 7; D006845:Hydrocarbons, Fluorinated; D014315:Triterpenes; C476029:Boc-D-FMK; C489897:silvestrol; D001572:Benzofurans
references: J Biol Chem. 1997 Apr 11;272(15):9677-82
references: 9092497
references: Cancer Res. 1997 May 1;57(9):1758-68
references: 9135020
references: Cancer Res. 1997 Sep 15;57(18):3941-3
references: 9307276
references: Cancer Res. 1998 Jan 1;58(1):76-83
references: 9426061
references: Chem Biol Interact. 1998 Oct 2;115(3):215-28
references: 9851291
references: Cancer Res. 1999 Jan 15;59(2):382-90
references: 9927051
references: Z Naturforsch C. 1999 Jan-Feb;54(1-2):55-60
references: 10223787
references: Mol Cancer Ther. 2004 Nov;3(11):1385-96
references: 15542777
references: J Nat Prod. 2004 Dec;67(12):2141-53
references: 15620274
references: Mol Pharmacol. 2005 May;67(5):1544-55
references: 15716464
references: J Immunol. 2005 Jun 1;174(11):7075-84
references: 15905551
references: J Org Chem. 2004 May 14;69(10):3350-8
references: 15132542
references: Cell Signal. 2005 Feb;17(2):243-51
references: 15494215
references: J Exp Med. 1995 Aug 1;182(2):367-77
references: 7629499
references: Cancer Res. 2000 Nov 15;60(22):6259-65
references: 11103780
references: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13884-8
references: 11717445
references: J Biol Chem. 2001 Dec 7;276(49):46639-46
references: 11583996
references: Mol Cell Biol. 2002 Feb;22(3):724-36
references: 11784850
references: Trends Mol Med. 2002 May;8(5):212-20
references: 12067630
references: Apoptosis. 2002 Aug;7(4):313-9
references: 12101390
references: Curr Pharm Biotechnol. 2002 Sep;3(3):275-83
references: 12164482
references: Prostate. 2002 Dec 1;53(4):300-9
references: 12430141
references: J Biol Chem. 2002 Nov 22;277(47):44791-800
references: 12237314
references: Science. 2003 Jan 10;299(5604):214-5
references: 12522239
references: Cell Death Differ. 2003 Jan;10(1):101-7
references: 12655298
references: J Nat Prod. 2003 Jul;66(7):1022-37
references: 12880330
references: Nat Med. 2000 May;6(5):529-35
references: 10802708
references: Z Naturforsch C. 1999 Dec;54(12):1075-83
references: 10685499
references: Curr Opin Cell Biol. 2003 Dec;15(6):725-31
references: 14644197
references: Int J Cancer. 2004 May 10;109(6):933-40
references: 15027128